MTOR and renal cell carcinoma: The subsequent application of vascular endothelial growth factor (VEGF), tyrosine kinase inhibitors (TKIs), and mammalian target of rapamycin (mTOR) inhibitors has improved the efficacy and safety of RCC systemic treatment [6].